Numerous therapeutic agents and antibodies have been developed targeting IGF-1R, EGRR and VEGFR signaling pathways with intention to block cancer cell proliferation, angiogenesis or revert drug resistance [31,32]. The gene discussed is IGF1R; the disease is cancer.